The classic website will no longer be available as of June 25, 2024. Please use the modernized
Working… Menu

Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13) (HYPERION)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04811092
Recruitment Status : Recruiting
First Posted : March 23, 2021
Last Update Posted : May 31, 2024
Information provided by (Responsible Party):
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : August 27, 2026
Estimated Study Completion Date : December 27, 2029